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Abstract
Recently, VOLO™ was introduced as a new optimizer for CyberKnife® planning. In
this study, we investigated possibilities to improve treatment plans for MLC‐based
prostate SBRT with enhanced peripheral zone dose while sparing the urethra, and
central lung tumors, compared to existing Sequential Optimization (SO). The primary
focus was on reducing OAR doses. For 25 prostate and 25 lung patients treated
with SO plans, replanning with VOLO™ was performed with the same planning con-
straints. For equal PTV coverage, almost all OAR plan parameters were improved
with VOLO™. For prostate patients, mean rectum and bladder doses were reduced
by 34.2% (P < 0.001) and 23.5% (P < 0.001), with reductions in D0.03cc of 3.9%,
11.0% and 3.1% for rectum, mucosa and bladder (all P ≤ 0.01). Urethra D5% and
D10% were 3.8% and 3.0% lower (P ≤ 0.002). For lung patients, esophagus, main
bronchus, trachea, and spinal cord D0.03cc was reduced by 18.9%, 11.1%, 16.1%,
and 13.2%, respectively (all P ≤ 0.01). Apart from the dosimetric advantages of
VOLO™ planning, average reductions in MU, numbers of beams and nodes for pros-
tate/lung were 48.7/32.8%, 26.5/7.9% and 13.4/7.9%, respectively (P ≤ 0.003).
VOLO™ also resulted in reduced delivery times with mean/max reductions of: 27/
43% (prostate) and 15/41% (lung), P < 0.001. Planning times reduced from 6 h to
1.1 h and from 3 h to 1.7 h for prostate and lung, respectively. The new VOLO™
planning was highly superior to SO planning in terms of dosimetric plan quality, and
planning and delivery times.
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1 | INTRODUCTION
Recently, the novel VOLO™ inverse treatment planning optimizer for
SBRT planning for the CyberKnife® System (CK) was implemented
in the Precision® treatment planning system (Accuray Inc,
Sunnyvale, USA). VOLO™ has major differences in optimization
approach compared to the existing Sequential Optimization (SO).
Three recent studies showed increased plan efficiency for VOLO™1–3
compared to SO. All three studies were performed with a limited
number of patients per tumor site: five to ten. Schüler et al.1
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compared the VOLO™ and SO algorithms for five prostate cancer
patients for treatment with the InCise™ MLC. The study by Calusi
et al.2 included seven prostate cancer patients planned with MLC. In
both studies, five fractions of 7.25 Gy were delivered, without expli-
cit intra‐prostatic dose shaping to spare the urethra. For lung tumors
(location not specified), a VOLO™‐SO comparison was only made for
the IRIS™ variable aperture collimator.3 As it was hypothesized that
VOLO™ might provide better dosimetric results for complex SBRT
treatments,2 we decided to compare VOLO™ with SO for twenty‐
five prostate cancer patients with complex intra‐tumor dose pre-
scription, and 25 central lung cancer patients. All plans were made
for treatment with the InCise™ 2 MLC. Primary aim was to explore
whether VOLO™ planning could be used to further minimize OAR
doses, aside from possible efficiency improvements, e.g., regarding
delivery times and MU. Compared to,1,2 our prostate plans had an
enhanced complexity as brachytherapy‐like dose distributions were
generated, with enhanced dose in the peripheral zone, while selec-
tively avoiding the highest doses in the urethra.4,5 With higher dose
per fraction (4 × 9.5 Gy), our planning protocol was more challeng-
ing, as also lower dose‐volume constraints for rectum and bladder
were required. For lung cancer, the new VOLO optimizer was chal-
lenged with central tumors, where OARs are closer to the target
making the treatment protocol more difficult to be fulfilled than in
peripheral tumors.
2 | METHODS
2.A | Treatment unit
In this study, plans were prepared for CyberKnife® M6 system, as
used in our center and equipped with three types of collimation:
fixed cones, IRIS™ collimator (both producing circular fields of diame-
ter between 5 and 60 mm) and the InCise™ 2 MLC.6–11 The latter
can produce a maximum field size of 11.5 cm × 10 cm using 26 pairs
of leafs of 3.85 mm width @ SAD 800 mm. In this study, all SO and
VOLO plans were optimized for treatment with the MLC.
2.B | Optimization algorithms and application
2.B.1 | Sequential optimization (SO)
SO has been described in detail in the literature.6,12,13 Here, a short
summary is provided. In SO, MLC segments are generated based on
Beam’s‐Eye‐View projections (conformal with or without OAR cut-
outs; eroded, perimeter and random shapes are allowed). Next, the
segment weights are optimized in a stepwise optimization approach
utilizing linear programming. The user can define hard planning con-
straints and objectives. Each objective is individually optimized, in
order of attributed priority, without violating imposed constraints.
After each objective optimization, an extra constraint is added to the
optimization problem; the involved objective is transformed into a
constraint with a slightly relaxed attained objective value. After initial
optimization, a node and segment reduction and reoptimization itera-
tive procedure can be applied to limit treatment time. The latter was
done for all SO plans used in this study. The optimizations run on a
CPU.
2.B.2 | VOLO™
Plan optimization with VOLO™ is based on a weighted‐sum cost
function; there are no hard constraints.1–3,6 This cost function com-
bines multiple dose‐volume terms, with corresponding user‐defined
weighting factors. In a first phase, optimal fluence maps are gener-
ated while including a fluence smoothness term in the cost func-
tion, with a user‐defined weighting factor. A variant of the quasi
Newton algorithm, L‐BFGS‐B, is used as optimizer.14 Each fluence
map is then segmented to generate a set of initial MLC apertures
that comply with the physical limitations of the MLC. Segment opti-
mization follows the fluence optimization and is divided into three
phases. In preadaptation, the fluence optimization result is seg-
mented and dose is recalculated for each defined segment and then
the segment weights are reoptimized.15 The cost function is the
same as that used during fluence optimization except that the
smoothness penalty is replaced by a total MU penalty. In the
preadaptation phase, the segment weight optimization is performed
iteratively with low MU segments removed at each iteration. Subse-
quently, leaf position adaptation is performed to fine tune the aper-
tures.16 Finally, in the post adaptation phase, dose is recalculated
for the adjusted segments and segment weights are reoptimized
together with iterative pruning of low MU segments. VOLO™ opti-
mization is implemented on a GPU. It should be noted that both
SO and VOLO™ provide an option to select a randomized and spa-
tially distributed subset of nodes prior to optimization. This was not
used for any of the plans in this study. Instead for both SO and
VOLO™, optimization started with all possible nodes available in
the selected robot motion path.
2.B.3 | Treatment planning
Both for prostate and lung, SO was used for generation of the clini-
cal plans that were used in this study for comparison with VOLO™.
The SO plans were made by expert CK planners, acknowledging the
planning complexity and the need for high‐quality plans because of
the delivered high fraction and total doses. The VOLO™ plans were
generated by a postdoctoral researcher/medical physicist (MG) who
started the project without prior experience in CK or SBRT planning.
This VOLO™ planner first received a brief introduction to the system
by an Accuray representative. Next, a similar training procedure was
applied for both tumor sites: after discussions with a CK planner
(WT) and treating clinicians (KdV or JN), plans were generated for
five arbitrarily selected training patients. In this training phase, the
planner had access to the SO plans of the training patients, and
plans were iteratively improved by feedback of the expert planner or
clinicians. After the training phase, the postdoc generated the plans
for the other twenty study patients, without having knowledge of
the clinical dose distributions and without feedback by the expert
planner or clinicians.
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2.B.4 | Plan evaluation and comparison
Both for prostate and lung, VOLO™ plans for ten arbitrarily selected
patients were evaluated by a clinician to decide whether the plans
were acceptable for clinical use. To this purpose, the plans were
shown to the physician in the Precision TPS who examined the dose
distribution in CT slices and DVHs considering protocol constraints.
In this procedure, the clinicians had no access to the clinically deliv-
ered SO plan. VOLO™ and SO plans were renormalized to exactly
meet the clinically requested PTV coverage, followed by comparisons
of dosimetric and nondosimetric plan parameters (MU, estimated
treatment time, and number of nodes, beams and segments), see
details for both tumor sites below. Conformity Index (CI) was calcu-
lated as volume receiving the prescribed dose divided by PTV. Near‐
maximum dose, D0.03cc, was reported as a surrogate of Dmax.
17 To
assess plan complexity, the average weighted segment size (WSS)
and the Modulation Complexity Score (MCS,18) were calculated. A
plan can achieve MCS values from 0 (the highest complexity) to 1
(the lowest complexity). For VOLO™, planning times were measured,
while for the clinical SO planning the planning times were estimated
by planners.
2.C | Prostate
2.C.1 | Patients and planning protocol
The twenty‐five arbitrarily selected prostate patients included in the
study were treated in our clinic between November 2016 and
August 2019. Total dose was delivered in four daily fractions of
9.5 Gy (38 Gy total dose). PTV dose distributions were intentionally
heterogeneous with enhanced dose in the peripheral zone while
restricting the urethra dose.4,5 The PTV coverage goal was 95%, with
an imposed maximum dose of 62.5 Gy. The intention was to limit
Dmax for rectum to 38 Gy, for rectal mucosa to 28.5 Gy, and for
bladder to 41.8 Gy, and to keep near‐maximum doses, D1cc, in rec-
tum and bladder below 32.3 Gy and 38 Gy, respectively. When con-
sidered unfeasible, the 1 cc could be enlarged to 1.2 cc and 1.5 cc,
respectively. The goal was to keep urethra D50%, D10% and D5%
below 40 Gy, 42 Gy and 45.5 Gy, respectively. Femoral heads
should receive less than 24 Gy. No beams were allowed to pass
through the penis and scrotum.
2.C.2 | SO and VOLO™ planning
All clinical plans were generated with SO as implemented in TPSs
supplied by Accuray Inc; seven with MultiPlan 5.3.0, and eighteen
with Precision 1.1.1.1. In both TPSs, the implementation of SO was
the same. All VOLO™ plans were generated in Precision 2.0.0.0. The
same dose calculation algorithm, i.e., Finite Size Pencil Beam (FSPB),
treatment machine (above) and prostate node path (full or short as
decided during clinical planning) were used for SO and VOLO™. In
order to create VOLO™ plans with a similar PTV dose as SO, the
average mean PTV dose in the 25 SO plans was used for guidance
in the VOLO™ planning. For 12 out of 25 SO plans, an additional
blocking structure was used to avoid beams going through the belly.
This structure was omitted in VOLO™ planning. In SO plans, hetero-
geneous dose distributions were obtained by dividing the PTV into a
peripheral (outer 5mm) and an inner zone (without urethra), and
using different planning objectives for them. To obtain inhomoge-
neous PTV doses with VOLO™ planning, the PTV with subtracted
OARs was added as an extra planning structure with objectives for
dose enhancements: V60% ≥ 48Gy and V25% ≥ 55Gy (with possible
small patient‐specific variation). Urethra high dose was controlled by
using dedicated constraints (SO) or objectives (VOLO™). According
to general clinical practice, if achieving desired 95% PTV coverage
and fulfilling OARs constraints as specified in planning protocol was
not possible at the same time, PTV coverage was reduced until
OARs constraints were met.
2.C.3. | Plan evaluations and comparisons
Prior to the pairwise dosimetric comparisons of SO and VOLO™
plans, all plans were normalized to have the clinically requested PTV
coverage of 95%. Estimated delivery times were calculated for
120 sec imaging intervals. Patient setup time was not included.
2.D | Lung
2.D.1 | Patients and planning protocol
Twenty‐five central lung cancer patients treated in our clinic
between March 2019 and January 2020 were replanned with
VOLO™. Patients were treated with five daily fractions of 11 Gy.
The PTV was aimed to have a coverage of 98% with a maximum
dose between 69 Gy and 78.57 Gy. The intention was to limit Dmax
in the spinal cord to 27 Gy, in the trachea to 45 Gy, in the main
bronchus to 50 Gy, in the plexus brachialis to 30 Gy, and in the
esophagus, stomach, bowel and skin to 35 Gy. When 30 Gy was
considered infeasible, 40 Gy could be accepted as Dmax in esopha-
gus. The goal was to keep lung V16Gy below 31 %, and thoracic wall
V30Gy below 30 cc.
2.D.2 | SO and VOLO™ planning
Nineteen clinical plans were generated with Precision 1.1.1.1, and six
with Precision 2.0.1.1, with both systems having the same SO imple-
mentation. All VOLO™ plans were generated in Precision 2.0.1.1. The
same treatment machine (above), nodes path (full or short as decided
during clinical planning) and blocking structures were used for plan-
ning in SO and VOLO™. For SO, a first optimization was done with
FSPB with Lateral Scattering (FSPB + LS) and after achieving satisfac-
tory results optimization with the Monte Carlo dose calculation engine
(MC) was performed with parameters found previously. With VOLO™,
FSPB is used during fluence optimization, FSPB + LS in the preadap-
tation phase of segment optimization, while MC was used in the
postadaptation phase. For final dose calculations in VOLO™, MC was
used for the same requested uncertainty as used for SO. In order to
create VOLO™ plans with similar PTV doses as obtained with SO,
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maximum SO PTV doses were used to guide the VOLO™ planning. To
overcome the lack of MC in the VOLO™ fluence optimization step
and therefore lack of dose in low‐density regions of PTV surrounding
GTV, the additional structure called PTV‐ring (PTV minus GTV minus
OARs) was used with higher minimum dose set as objective for all
VOLO™ plans. According to general clinical practice, if achieving
desired 98% PTV coverage and fulfilling OARs constraints as specified
in planning protocol was not possible at the same time, PTV coverage
was reduced until OARs constraints were met, similar as for prostate
cancer (above).
2.D.3 | Plan evaluations and comparisons
Prior to the pairwise comparisons of SO and VOLO™ plans, all plans
were normalized to have the same, clinically requested PTV coverage
of 98%. Delivery time calculations were made for 60 sec imaging
intervals. Patient setup time was not included.
2.E | Statistics
Two‐sided Wilcoxon signed‐rank tests were used for statistical anal-
yses with p‐values lower than 0.05 indicating statistical significance.
3 | RESULTS
3.A | Prostate
3.A.1 | Clinical acceptability of original VOLO™
plans
For the evaluating clinician (KdV), all plans in the arbitrarily selected
subset of 10 patients were clinically acceptable.
3.A.2 | PTV coverage and dose
Prior to renormalization, PTV coverages achieved with SO ranged
from 86.7% to 98.1%, with in total 15 patients below 95%. Two
patients had a coverage below 90%, eight – between 90% and 94%,
and five between 94% and 95%. Plans created with VOLO™ had
PTV coverages between 89% and 95.1%, with only five patients
below 95%. Of those five patients, one had a coverage below 90%,
two – 93%, and two between 94.5% and 95%.
For all 15 patients with an SO plan with PTV coverage < 95%, the
VOLO™ optimizer could achieve 95% coverage for twelve of them.
For the other three patients, VOLO™ increased it from/to 86.7/93.0%,
87.9/89.0%, 93.6/94.5%, while fulfilling all OAR constraints. For
patient 21, PTV coverage with VOLO™ was 93% while the SO plan
had a coverage of 95%, because of a clinically accepted violation in
bladder V38Gy, not reproduced in the VOLO™ plan. Tradeoffs for all
prostate patients are presented in electronic Appendix S1.
In Fig. 1(a) population mean PTV DVHs after renormalization to
95% are presented, showing large similarity for the two planning
approaches. Table 1 also demonstrates that PTV D98%, D0.03cc, and
the CI were similar.
3.A.3 | OAR and patient dose
For similar PTV dose, VOLO™ plans performed on average better
than SO plans in almost all the studied parameters (Table 1). Rectum
and bladder D1cc were on average reduced by 4.7% with reductions
up to 20.5% and 12.1%, respectively. Mean/maximum reduction in
rectum and bladder Dmean were 34.3%/45.8% and 23.5%/41.0%,
respectively. Also high urethra doses were reduced in the VOLO™
plans, with mean/maximum reductions of 3.8%/14.9% and 3.0%/
14.0% in D5% and D10%, respectively. The patient volume receiving
5 Gy or more was reduced by 8% (maximum 18.3%) in the VOLO™
plans with increases in volumes receiving higher doses, as visible in
Table 1. Fig. 2 shows that the superiority of VOLO™ in OAR plan
parameters was observed for all patients. In Fig. 3 dosimetric plan
parameters are presented together with constraint and objective val-
ues, showing fewer and smaller violations for VOLO™. Dose distribu-
tions for a representative patient are shown in Fig. 4. Population
mean DVHs are presented in Appendix S2, showing reduced spread
of rectum and bladder doses, and urethra high doses with VOLO™.
3.A.4 | Nondosimetric plan parameters
The VOLO™ prostate plans were highly favorable in terms of plan
complexity and treatment time. The average WSS was significantly
(a) (b)
F I G . 1 . Comparison of SO and VOLO™
in terms of population mean PTV DVHs
for prostate (a) and lung (b).
4 | GIŻYŃSKA ET AL.
increased with VOLO™ as compared to SO (873.0 mm2 vs
451.0 mm2, P < 0.001). The MCS for VOLO™ was comparable to
SO (0.49 vs 0.50, P = 0.2), showing similar complexity of SO and
VOLO™ plans. With a comparable number of total MLC segments,
mean/maximum reductions in MU were 48.7%/66.4%, and the num-
ber of beams and nodes were reduced by 26.5%/57.0% and 13.4%/
42.0%, respectively (see Table 1 and Fig. 5). On average the esti-
mated delivery time was reduced by 8 min (from 29.5 min to
21.5 min), with a maximum reduction of 15 min. All these reductions
were statistically significant. Clinical SO planning took between 2
and 12 h (mean ~ 6 h), depending on the complexity of the case.
For VOLO™ plans, the planning time was on average 1 h 10 min,
with a range of 10 min to 3 h and 20 min.
3.B | Lung
3.B.1 | Clinical acceptability of original VOLO™
plans
For the evaluating clinician (JN), all plans in the arbitrarily selected
subset of 10 patients were clinically acceptable.
TAB L E 1 Comparisons of plan parameters for prostate cancer patients for plans generated with SO and VOLO™.
SO VOLO™ SO‐VOLO™a
P‐valuebMean Range Mean Range Mean [%] Range [%]
PTV
D98% [Gy] 35.2 [33.4, 37.3] 35.1 [32.6, 36.2] 0.3 [−4.9, 4.7] 0.5
D0.03cc [Gy] 62.2 [54.3, 72.8] 61.3 [59.1, 67.7] 0.9 [−11.4, 16.5] 0.4
CI 1.2 [1.1, 1.4] 1.2 [1.1, 1.3] −2.1 [−12.2, 11.0] 0.1
Rectum
D0.03cc [Gy] 37.7 [35.2, 43.0] 36.2 [34.1, 41.6] 3.9 [−3.3, 15.4] <0.001
D1cc [Gy] 31.6 [27.5, 36.6] 30.0 [26.4, 33.3] 4.7 [−2.3, 20.5] <0.001
Dmean [Gy] 11.6 [9.3, 15.9] 7.6 [5.3, 9.8] 34.3 [20.9, 45.8] <0.001
V40GyEq [%] 9.5 [4.2, 15.9] 6.0 [3.2, 10.7] 34.5 [−6.1, 66.5] <0.001
V60GyEq [%] 3.5 [1.5, 6.6] 2.4 [1.1, 4.0] 27.7 [−21.0, 71.9] <0.001
Rectal Mucosa
D0.03cc [Gy] 29.0 [26.8, 34.0] 25.7 [23.3, 27.6] 11.0 [0.0, 31.5] <0.001
Bladder
D0.03cc [Gy] 42.2 [39.0, 51.7] 40.8 [38.7, 46.9] 3.1 [−14.1, 16.9] 0.01
D1cc [Gy] 38.7 [34.6, 44.5] 36.9 [34.1, 42.7] 4.7 [−7.6, 12.1] <0.001
Dmean [Gy] 12.3 [8.1, 17.3] 9.3 [7.1, 12.3] 23.5 [−10.0, 41.0] <0.001
Urethra
D5% [Gy] 43.1 [39.7, 50.9] 41.4 [39.5, 45.4] 3.8 [−3.9, 14.9] 0.001
D10% [Gy] 42.3 [39.4, 49.9] 41.0 [39.1, 45.1] 3.0 [−3.8, 14.0] 0.002
D50% [Gy] 40.0 [36.6, 46.3] 39.7 [38.0, 43.8] 0.7 [−4.6, 10.6] 0.4
Body
V5Gy [cc] 2576.4 [1754.3, 3565.8] 2342.7 [1687.4, 2980.4] 8.0 [−30.1, 18.3] <0.001
V10Gy [cc] 871.9 [436.2, 1721.6] 938.8 [632.7, 1218.8] −13.6 [−67.2, 29.7] 0.04
V20Gy [cc] 207.1 [118.9, 359.7] 217.2 [138.4, 295.0] −6.5 [−26.4, 18.0] 0.01
V30Gy [cc] 110.6 [64.7, 176.4] 114.1 [73.6, 158.1] −4.2 [−13.8, 10.3] 0.01
Plan Parameters
MU 47377 [33598, 60794] 23524 [19873, 35512] 48.7 [6.9, 66.4] <0.001
WSS [mm2] 451.0 [320.4, 660.0] 873.0 [560.6, 1248.5] −97.5 [−161.2, −10.5] <0.001
MCS 0.49 [0.31, 0.61] 0.50 [0.33, 0.60] −5.9 [−51.3, 27.3] 0.2
NoF Beams 73.9 [51,115] 47.4 [37,59] 26.5 [6.0, 57.0] <0.001
NoF Nodes 60.9 [46,90] 47.4 [37,59] 13.4 [−2.0, 42.0] <0.001
NoF Segments 107.2 [54,235] 92.9 [54,167] 8.9 [−72.5, 62.1] 0.06
Estimated Delivery Time [min] 29.5 [20.1, 38.3] 21.5 [16.6, 31.6] 26.7 [−3.6, 42.5] <0.001
apercentage values are given as: (SO‐VOLO™)*100/SO.
bBold P‐values represent statistically significant results (P < 0.05).
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3.B.2 | PTV coverage and dose
PTV coverage achieved with SO ranged from 89.3% to 99.2%. Nine
patients had SO PTV coverage below 98%; three between 89.3%
and 97%, and six between 97% and 98%. Plans created with
VOLO™ had a PTV coverage between 91.6% and 98.1%; of the
three patients with a VOLO™ coverage below 98%, one patient had
a coverage of 91.6%, and two between 97.5% and 98%. As men-
tioned in the Methods section, the aim was to generate for each
patient a VOLO™ plan with a PTV Dmax similar to the one in the SO
plan. As shown in Table 2, a small difference of 1.9% in D0.03cc was
found, which was considered of minor clinical importance.
For patient 23 with the lowest clinically achieved PTV coverage
(89.3%), the constraint for stomach Dmax was limiting. With
VOLO™, it was possible to increase the coverage to 91.6% while
keeping the stomach dose within the constraint. For this patient,
there was a higher bowel dose observed for VOLO™, which was
however far from constraint. Patient 23 was the only patient with
stomach and bowel structures involved. Therefore, no statistical
analyses could be performed for these OARs. Patient 14 had a
tumor located close to spinal cord. A PRV (spinal cord + 5 mm
margin) was therefore used for planning of this patient instead of
the spinal cord itself. Related to this, a PTV coverage of 95.9%
was accepted for the clinical SO plan. With VOLO™ it was possible
to reduce the spinal cord maximum PRV dose by 4.4 Gy, while
keeping 98% PTV coverage. The main bronchus was in SO planning
a limiting structure for patient 25, the achieved PTV coverage was
95.3%. With VOLO™ it was possible to increase the coverage to
97.5%, while still keeping the main bronchus Dmax within con-
straint. Tradeoffs for all lung patients are presented in electronic
Appendix S3.
Population mean PTV DVHs after renormalization to the pre-
ferred coverage of 98% for each patient are presented in Fig. 1(b),
showing large similarity for SO and VOLO™.
F I G . 2 . Comparison between SO and VOLO™ in OAR dose parameters for prostate SBRT. Bars present differences between SO and
VOLO™ results. Positive values indicate that VOLO™ is favorable.
6 | GIŻYŃSKA ET AL.
3.B.3 | OAR and patient doses
After renormalization of all SO and VOLO™ plans to a PTV coverage
of 98%, VOLO™ plans performed on average better than SO plans
in most healthy tissues (Table 2), with large variations among
patients (Fig. 6). Esophagus, main bronchus, spinal cord, and trachea
D0.03cc were on average reduced by 18.9%, 11.1%, 13.2%, and
16.1% with maximum reductions up to 70.9%, 57.6%, 65.9%, and
45.5%, respectively. Mean/maximum reduction in esophagus, spinal
cord and thoracic wall Dmean were 13.4%/62.8%, 11.2%/70.1% and
2.7%/16.8%, respectively. Also, thoracic wall D30cc was reduced in
VOLO™ plans, with mean/maximum reductions of 4.4%/18.0%. Lung
dose was comparable. The patient volume receiving 5 Gy or more
was reduced by 3.8% (maximum 19.2%) in the VOLO™ plans with
similar volumes receiving higher doses. In Fig. 7 dosimetric plan
parameters are presented together with constraint and objective val-
ues. Dose distributions for a representative patient are shown in
Fig. 8. Appendix S4 shows population mean DVHs for the investi-
gated planning approaches.
3.B.4 | Nondosimetric plan parameters
The VOLO™ lung plans were favorable in terms of plan complexity
and treatment time. The average WSS was significantly increased
with VOLO™ as compared to SO (864.3 mm2 vs 532.6 mm2,
P < 0.001). The MCS for VOLO™ was on average higher compared
to SO (0.53 vs. 0.43, P < 0.001), showing smaller average complexity
of VOLO™ plans. Mean/maximum reductions in MU were 32.8%/
51.4%, and the number of beams, nodes and segments was reduced
by 7.9%/31.0% and 7.9%/31.0% and 10.5%/45.7%, respectively (see
Table 2 and Fig. 5). On average, the estimated delivery time was
reduced by 3.7 min (from 25.4 min to 21.6 min), with a maximum
reduction of 10 min. All these reductions were statistically signifi-
cant. Clinical SO planning took between 1 and 8 h (mean ~ 3 h),
depending on the complexity of the case. For VOLO™, the planning
time was on average 1 h 40 min, with a range of 30 min to 6 h.
4 | DISCUSSION
The main goal of this study was to validate the new VOLO™ opti-
mizer for treatment planning for MLC‐based robotic SBRT for pros-
tate cancer with intended urethra sparing, and for central lung
tumors with many OARs nearby. As summarized in the Methods sec-
tion, VOLO™ has a rather different inverse planning approach com-
pared to the existing SO, it uses a quasi‐Newton optimizer with fast
convergence14 and it operates with faster computer hardware (GPU
vs. CPU). For 25 prostate and 25 lung cancer patients, previously
treated with robotic SBRT with an SO plan, VOLO™ was used for
replanning for the same planning aims as used for the clinical SO
F I G . 3 . Mutual comparisons of SO and VOLO™ dosimetric prostate plan parameters. The horizontal and vertical colored lines show
constraint (solid) and objective (dashed) values. Markers in the gray area point at superiority of VOLO™. Observed constraint violations
(especially seen for SO) are due to the fixed PTV coverage of 95%.
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planning. For prostate cancer, the VOLO™ plans were dosimetrically
highly superior compared to the clinically delivered plans, which held
for all OARs and patients. For lung cancer there was also an overall
dosimetric gain with VOLO™, but it was more dependent on OAR
and patient. For both treatment sites there were large gains in num-
ber of MU and number of beams and nodes, with clinically relevant
reductions in treatment delivery times. Observed reductions in plan-
ning time were also large. In our opinion, the observed enhanced
OAR sparing with VOLO™ is clinically meaningful and the reduced
planning and treatment times are highly relevant from the logistical
point of view.
In principle, plan quality differences between SO and VOLO™
can originate from differences in beam segments/intensity profiles
and differences in selected beam directions, depending on nodes
and isocenter placement. In this study, for both prostate and lung,
planning with SO and VOLO™ started with the full set of available
nodes (Methods section), with some blocked because of applied
blocking structures. For prostate cancer, there were substantial dif-
ferences in both: the applied numbers of nodes, numbers of MLC
segments, WSS and total MU for SO/VOLO™ were 60.9/47.4, 107.2/
92.9, 451.0/873.0, 47377/23524. Of the on average 47.4 nodes in
VOLO™ plans, only 67% were also present in the SO beam set.
Clearly, these differences in beam directions could have contributed
to the observed differences in plan quality. On the other hand, also
the numbers of segments, WSS and total MU were rather different,
pointing at differences in intensity profiles. For lung, total numbers
of nodes were rather similar: 45.5 for SO and 41.3 for VOLO™.
However, on average only 65.2% of directions used in SO were also
used in VOLO™. So effectively, also for lung there are substantial
differences in selected beam directions. However, also for lung,
differences in number of segments, WSS and total MU were signifi-
cant: 74.3/66.1, 532.6/864.3, 29265/19584 (SO/VOLO™) pointing at
differences in intensity profiles.
Schüler et al.1 also compared VOLO™ with SO. They investigated
six groups of five patients: simple brain treated with the IRIS™ vari-
able aperture collimator, complex brain treated with either the IRIS™
or the InCise™ MLC, complex spine treated with the IRIS™ or the
InCise™ MLC, and prostate treated with the InCise™ MLC. SO plan-
ning was used for treatment. For all patients, an alternative plan was
made with VOLO™, aiming to meet OAR constraints in the SO plans
and improve on MU and delivery time. In line with our study, they
also found reductions in MU and delivery time, which were a bit
smaller than we observed, i.e., −38% vs. −49% and −17% vs. −27%,
respectively. For the five prostate patients, they found only minor
differences in dosimetric plan quality. This is in contrast with the
results for the 25 prostate patients in our study; not only did we
observe drastically reduced MU and delivery times, but there were
also large dose reductions in healthy tissues (Table 1). This differ-
ence in OAR doses could possibly (partially) be explained by a differ-
ence in study design. While they used VOLO™ to reduce the MU
and delivery times for OAR doses similar to those obtained with SO
(above), we actively tried to reduce OAR doses as much as possible
(not knowing about obtained doses in the SO plans). Apparently,
VOLO™ planning by Schüler et al. did not result in better dosimetric
plan quality if not explicitly desired, or better quality could possibly
only be obtained with smaller gains in MU and delivery times. An
alternative (partial) explanation for the differences between the stud-
ies in OAR doses could be in the planning aims for the urethra. As
mentioned above, in our study the urethra dose was actively
restricted which resulted in a dose valley in and around the urethra.
This approach was not applied by Schüler et al. Probably, the
upfront geometrical segment generation in SO planning (Methods
section, 2.B.1.) was less suited for the inhomogeneous dose distribu-
tions required in our center, resulting in relatively large dosimetric
gains for VOLO™ in which segments are dosimetrically optimized.
Zeverino et al.3 compared SO and VOLO™ for brain, spine,
prostate, and lung cancer patients, treated with the circular IRIS™
collimator (10 patients per site). Another 10 brain patients were
planned for the InCise™ MLC to a different prescription dose. For
prostate and lung there were no MLC plans generated, complicating
comparisons with our study with MLC treatment only. In line with
the work by Schüler et al1 and our study, they also observed reduc-
tions in number of nodes (36%), number of beams (14%) and MU
(31%). For prostate patients, significant dose reductions were only
reported for the urethra, with averages of 66.7%, 75.0% and 5.2%
in V39Gy, V41Gy and Dmax, respectively. In our study, enhanced OAR
sparing with VOLO™ planning was largest for rectum and bladder
and less for the urethra. It is not clear to what extent this could be
caused by differences in the clinical planning aims or the use of dif-
ferent collimators, i.e., the InCise™ MLC in our study and the circu-
lar IRIS™ by Zeverino et al. For lung patients, Zeverino et al. did
not find differences in OAR doses achieved with SO and VOLO™,
while in our study large improvement was observed with VOLO™
F I G . 4 . Upper panels: example of dose distributions (SO – left,
VOLO™ ‐ right) for a prostate patient. Patient 19 was chosen as the
dose difference between SO and VOLO™ in rectum D0.03cc was for
this patient closest to population average. Structures shown are:
prostate and PTV – red, rectum – green and urethra – yellow. For
both plans, the lower panel shows a zoomed area around the
prostate.
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planning, depending on OAR and patient (Table 2). Possibly, this is
due to patient selection. In our study we included central lung
tumors, while patient type was not specified by Zeverino et al. Pos-
sibly, also the different collimation in the two centers contributes
to these differences.
Calusi et al.2 compared VOLO™ with SO for MLC‐based SBRT
for liver, prostate, pancreas, and spine. In total 25 patients were
included in their study, five to seven per location. The authors found
reductions in MU/prescribed dose, delivery time, number of nodes,
and number of segments of 19%, 15%, 12% and 23%, respectively.
However no significant differences in OAR doses were reported.
The three published studies1–3 and our study all show large
improvements in treatment efficiency (MU, numbers of beams, deliv-
ery times) with VOLO™ planning. On the other hand, enhanced OAR
sparing was only seen by Zeverino et al.3 and in our study. In both
studies improvements were seen for prostate cancer, but Zeverino
et al. only observed urethra sparing while in our study there was
also important sparing of rectum and bladder. Significant OAR spar-
ing in lung cancer treatment was only observed in our study. Study
design, case complexity and applied collimator seem to impact the
observations for OAR.
It was previously shown19,20 that knowledge‐based planning (us-
ing planning CT‐scans and plans from previously treated patients) for
predicting feasible constraints for use in SO planning for robotic
prostate SBRT could reduce dose in rectum and bladder. Recent
studies21,22 investigated SO planning based on patient‐specific con-
straints and objectives values, obtained from a preoptimization with
a system for automated multi‐criterial plan generation. It was
observed that with the preoptimized constraints and objectives, the
quality of the SO plans significantly improved compared to SO plan-
ning in clinical practice without the input of the preoptimizer. The
latter observations suggest that generating high‐quality plans with
SO can in practice be hindered by problems in finding optimal
patient‐specific constraints and objective values in the clinical inter-
active trial‐and‐error planning.
Interestingly, the enhanced OAR sparing in the VOLO™ plans as
observed in this study was obtained by a planner with no previous
experience in SBRT or CK planning, with planning times that were
often much reduced compared to clinical planning. Also here we
attribute the inferior quality of the SO plans at least in part to diffi-
culties for the clinical planners in steering the SO algorithm to the
best possible plans, i.e., finding optimal patient‐specific goal values
for the cost functions in the trial‐and‐error planning effort. In gen-
eral, our experience was that the trial‐and‐error planning was less
intuitive for SO than for the VOLO™ algorithm, making it harder to
find good constraints defining cost functions. Due to the enhanced
F I G . 5 . Comparison of nondosimetric plan parameters for prostate (green diamonds) and lung (red squares).
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calculation speed of the VOLO™ algorithm, more iterations could
be made for finding the appropriate cost functions. Influence of cal-
culation speed on plan quality was previously observed.23 The
difference between SO and VOLO™ in calculation speed could be
related to the difference in the applied computer hardware (GPU
vs. CPU) and improved optimizer convergence which is used
TAB L E 2 Comparisons of plan parameters for lung cancer patients for plans generated with SO and VOLO™.
SO VOLO™ SO‐VOLO™ a
Mean Range Mean Range Mean [%] Range [%] P‐valueb
PTV
D98% [Gy] 55.0 [54.9, 55.1] 55.0 [54.9, 55.1] 0.0 [−0.2, 0.2] 0.3
D0.03cc [Gy] 71.9 [67.3, 91.1] 73.2 [69.0, 89.6] ‐1.9 [−5.9, 1.7] 0.001
CI 1.2 [1.1, 1.8] 1.2 [1.1, 1.8] 0.6 [−14.4, 13.4] 0.5
Esophagus
D0.03cc [Gy] 15.4 [2.8, 35.0] 12.5 [1.5, 30.5] 18.9 [−4.4, 70.9] <0.001
Dmean [Gy] 3.8 [0.7, 10.8] 3.3 [0.4, 9.4] 13.4 [−38.8, 62.8] 0.002
Main Bronchus
D0.03cc [Gy] 20.1 [0.5, 50.0] 18.1 [0.4, 44.7] 11.1 [−101.5, 57.6] 0.003
Dmean [Gy] 6.2 [0.2, 18.1] 5.8 [0.2, 15.1] 7.6 [−42.6, 50.4] 0.1
Skin
D0.03cc [Gy] 12.6 [6.6, 18.9] 12.5 [7.0, 18.3] ‐1.9 [−52.3, 24.5] 0.7
Dmean [Gy] 0.5 [0.2, 0.9] 0.4 [0.2, 0.9] 2.8 [−2.9, 8.4] 0.002
Spinal Cord
D0.03cc [Gy] 11.8 [1.1, 25.1] 10.4 [0.9, 22.7] 13.2 [−48.6, 65.9] 0.01
Dmean [Gy] 2.2 [0.4, 4.7] 2.0 [0.2, 4.4] 11.2 [−32.9, 70.1] 0.02
Thoracic Wall
D30cc [Gy] 18.1 [7.3, 35.9] 17.0 [8.3, 29.9] 4.4 [−13.7, 18.0] 0.008
Dmean [Gy] 4.8 [1.3, 14.0] 4.6 [1.4, 12.7] 2.7 [−12.5, 16.8] 0.01
Trachea
D0.03cc [Gy] 9.9 [0.3, 41.3] 8.5 [0.2, 37.3] 16.1 [−23.1, 45.5] 0.001
Dmean [Gy] 2.4 [0.1, 8.8] 2.2 [0.1, 9.9] 11.9 [−16.1, 47.0] 0.08
Lung
V5Gy [%] 18.8 [3.3, 37.5] 18.7 [3.6, 38.5] 0.5 [−22.4, 12.8] 0.6
V16Gy [%] 5.6 [0.8, 11.4] 5.6 [0.8, 12.1] ‐1.7 [−19.8, 14.9] 0.5
V20Gy [%] 4.1 [0.6, 8.3] 4.1 [0.6, 8.5] ‐1.8 [−21.0, 13.9] 0.6
V30Gy [%] 2.3 [0.4, 4.7] 2.3 [0.4, 4.7] ‐1.4 [−20.5, 9.5] 0.6
Body
V5Gy [cc] 7.1 [2.0, 13.6] 6.9 [1.9, 13.5] 3.8 [−8.1, 19.2] 0.006
V10Gy [cc] 2.8 [0.6, 7.3] 2.8 [0.8, 6.9] 0.4 [−16.9, 20.8] 0.1
V20Gy [cc] 0.8 [0.2, 2.9] 0.8 [0.2, 2.8] 2.5 [−17.9, 20.8] 0.09
V30Gy [cc] 0.4 [0.1, 1.4] 0.4 [0.1, 1.4] 0.8 [−15.9, 17.1] 0.5
Plan Parameters
MU 29265 [19111, 40147] 19584 [14143, 33648] 32.8 [5.3, 51.4] <0.001
WSS [mm2] 532.6 [273.8, 1198.1] 864.3 [349.0, 2096.6] ‐58.4 [−116.2, −7.4] <0.001
MCS 0.43 [0.33, 0.53] 0.53 [0.45, 0.65] ‐24.6 [−74.4, 10.8] <0.001
NoF Beams 45.5 [34,63] 41.3 [32,61] 7.9 [−61.8, 31.0] 0.003
NoF Nodes 45.5 [34,63] 41.3 [32,61] 7.9 [−61.8, 31.0] 0.003
NoF Segments 74.3 [47,115] 66.1 [41,121] 10.5 [−75.9, 45.7] 0.02
Estimated Delivery Time [min] 25.4 [18.1, 34.5] 21.6 [15.6, 33.5] 14.5 [−30.2, 40.5] <0.001
apercentage values are given as: (SO‐VOLO™)*100/SO.
bBold P‐values represent statistically significant results (P < 0.05).
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without hard constraints. Additionally, the SO algorithm uses a
higher dose threshold when storing the per‐beam dose maps that
are used during optimization, which can cause larger differences
between the optimization result and the final dose calculation, pos-
sibly requiring additional optimization iterations for good solutions,
enhancing the total planning time. In this paper we compared the
combination (unexperienced planner/VOLO™) with (experienced
planner/SO). The technical advantages of VOLO™ compared to SO
(above) allowed the unexperienced planner to beat the experienced
planner in overall plan quality. Possibly, with the combination (ex-
perienced planner/VOLO™), plan quality could have been further
enhanced. At the time of the study, plan generation with this com-
bination was not feasible. On the other hand, this additional plan-
ning work would not have changed the main conclusion of the
paper: VOLO™ has the potential of increasing plan quality com-
pared to SO. The extra combination could only have further
strengthened this conclusion.
As mentioned above, another major difference between SO and
VOLO™ was the generation of the MLC segments. With SO, seg-
ment shapes are preselected based on beam’s‐eye‐view projections,
while in the VOLO™ algorithm, segment shapes are dosimetrically
optimized with the usage of objective functions used also in the flu-
ence optimization step. This difference may in part also be responsi-
ble for the observed overall higher quality of the VOLO™ plans,
especially for prostate cancer with the prescribed inhomogeneous
dose distributions with urethra sparing. This enhanced dosimetric
quality could be obtained with large reductions in MU, numbers of
beams and numbers of nodes, while the WSS was clearly increased
pointing at improved plan robustness. MCS for prostate was compa-
rable for SO and VOLO™ while being reduced with VOLO™ for
lung.
As demonstrated in this study, the applied inverse planning algo-
rithm can have a major impact on obtained plan quality. This needs
to be considered in treatment planning studies for treatment
F I G . 6 . Comparisons between SO and VOLO™ OAR dose parameters for all lung cancer patients separately. Bars present differences
between SO and VOLO™ results; positive value indicates that VOLO™ is favorable.
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technique comparisons; observed differences in plan quality can be
due to differences in techniques, but differences in applied optimiz-
ers can heavily bias the results especially if optimization is done
manually. Even more important, this study points at the need of con-
tinued research on optimization algorithms, and their use for bench-
marking clinical algorithms to avoid patient treatment on advanced
machines with suboptimal plans.
5 | CONCLUSIONS
In robotic SBRT with the InCise™ 2 MLC, the novel VOLO™ inverse
planning algorithm was highly superior compared to planning with
Sequential Optimization (SO) for two complex patient groups, i.e.,
prostate cancer treated with urethra sparing, and central lung
tumors. Apart from large dosimetric advantages, also MU, numbers
of beams, numbers of nodes, treatment delivery times, and planning
times substantially improved. Treatment times reduced by 8 min and
3.8 min for prostate and lung, respectively. This study points out
that more comparative studies on optimizers are needed. Such stud-
ies may raise awareness among users and TPS vendors of potential
weaknesses, and may avoid suboptimal treatment on high‐end treat-
ment units, and erroneous conclusions from treatment planning stud-
ies.
ACKNOWLEDGEMENTS
The authors wish to thank Warren Kilby and Colin Sims from Accu-
ray Inc (Sunnyvale, USA) for their introduction to the CK TPS and
for helpful comments on planning with VOLO™ optimization.
CONFLICT OF INTEREST
This work was in part funded by a research grant of Accuray Inc.
Erasmus MC Cancer Institute also has research collaborations with
Elekta AB Stockholm, Sweden. No additional external funding was
received for this study. The funders had no role in study design, data
F I G . 7 . Mutual comparisons of SO and VOLO™ dosimetric lung plan parameters. The horizontal and vertical colored lines show constraint
(solid) and objective (dashed) values. Markers in the gray area point at superiority of VOLO™. Observed constraint violations (especially seen
for SO) are due to the fixed PTV coverage of 98%.
F I G . 8 . Upper panels: example of dose distributions (SO – left,
VOLO™ ‐ right) for lung patient. Patient 1 was chosen as the dose
difference between SO and VOLO™ in main bronchus D0.03cc was
for this patient closest to population average. Structures shown are:
CTV and PTV – red, esophagus ‐ green, spinal cord ‐ yellow and
main bronchus – blue. For both plans, the lower panel shows a
zoomed area around the target volume.
12 | GIŻYŃSKA ET AL.
collection and analysis, and decisions on preparation of the manu-
script and publication.
AUTHOR CONTRIBUTION
Marta K. Giżyńska: study design and concept, data collection and
analysis, manuscript writing. Linda Rossi: study design and concept,
manuscript revision. Wilhelm den Toom: data collection and interpre-
tation, manuscript revision. Maaike T. W. Milder: data interpretation,
manuscript revision. Kim C. de Vries: data analysis, manuscript revi-
sion. Joost J. Nuyttens: data analysis, manuscript revision. Ben J. M.
Heijmen: study design and concept, manuscript revision.
REFERENCES
1. Schüler E, Lo A, Chuang C, Soltys S, Pollom E, Wang L. Clinical
impact of the VOLO optimizer on treatment plan quality and clinical
treatment efficiency for CyberKnife. J Appl Clin Med Phys. 2020;1–
10. https://doi.org/10.1002/acm2.12851.
2. Zeverino M, Marguet M, Zulliger C, et al, Novel inverse planning
optimization algorithm for robotic radiosurgery: first clinical imple-
mentation and dosimetric evaluation. Physica Med. 2019;64:
230–237.
3. Calusi S, Doro R, Di Cataldo V, et al, Performance assessment of a
new optimization system for robotic SBRT MLC‐based plans. Physica
Med. 2020;71:31–38.
4. Aluwini S, van Rooij P, Hoogeman M, et al, CyberKnife stereotactic
radiotherapy as monotherapy for low‐ to intermediate‐stage prostate
cancer: early experience, feasibility, and tolerance. J Endourol.
2010;24:865–869.
5. Aluwini S, van Rooij P, Hoogeman M, et al, Stereotactic body radio-
therapy with a focal boost to the MRI‐visible tumor as monotherapy
for low‐ and intermediate‐risk prostate cancer: early results. Radiat
Oncol. 2013;8:84.
6. Kilby W, Naylor M, Dooley JR, Maurer CR, Sayeh S. A Technical
Overview of the CyberKnife System. Handbook of Robotic and
Image‐Guided Surgery. Elsevier. 2020;15–38.
7. Echner GG, Kilby W, Lee M, et al, The design, physical properties
and clinical utility of an iris collimator for robotic radiosurgery. Phys
Med Biol. 2009;54:5359–5380.
8. Fürweger C, Prins P, Coskan H, Heijmen BJM. Characteristics and
performance of the first commercial multileaf collimator for a robotic
radiosurgery system. Med Phys. 2016;43:2063–2071.
9. Fürweger C, Prins P, Coskan H, et al, Performance evaluation of the
first two generations of multi‐leaf collimators for a robotic radio-
surgery system. Cureus. 2016;8:a123.
10. Asmerom G, Bourne D, Chappelow J, et al, The design and physical
characterization of a multileaf collimator for robotic radiosurgery.
Biomedical Physics Engineering Express. 2019;2.
11. Papalazarou C, Klop GJ, Milder MTW, et al, CyberKnife with inte-
grated CT ‐on‐rails: system description and first clinical application
for pancreas SBRT. Med Phys. 2017;44:4816–4827.
12. Schlaefer A, Schweikard A. Stepwise multi‐criteria optimization for
robotic radiosurgery. Med Phys. 2008;35:2094–2103.
13. CyberKnife Robotic Radiosurgery System – Physics Essentials Guide,
Accuray Incorporated.
14. Byrd R, Peihuang L, Nocedal J, Zhu C. A limited memory algorithm
for bound constrained optimization. SIAM J Sci Comput.
1995;16:1190–1208.
15. Xia P, Verhey LJ. Multileaf collimator leaf sequencing algorithm for
intensity modulated beams with multiple static segments. Med Phys.
1998;25:1424–1434.
16. Cassioli A, Unkelbach J. Aperture shape optimization for IMRT treat-
ment planning. PMB. 2013;58:301–318.
17. Li X, Kabolizadeh P, Yan DI, et al, Improve Dosimetric Outcome in
Stage III non‐small‐cell lung cancer treatment using spot‐scanning
proton arc (SPArc) Therapy. Rad Onc. 2018;13:35.
18. McNiven AL, Sharpe MB, Purdie TG. A new metric for assessing
IMRT modulation complexity and plan deliverability. Med Phys.
2010;37:505–515.
19. Descovich M, Carrara M, Morlino S, et al, Improving plan quality and
consistency by standardization of dose constraints in prostate cancer
patients treated with CyberKnife. J Appl Clin Med Phys. 2013;14:
162–172.
20. Wu B, Pang D, Lei S, et al, Improved robotic stereotactic body radia-
tion therapy plan quality and planning efficacy for organ‐confined
prostate cancer utilizing overlap‐volume histogram‐driven planning
methodology. Radiother Oncol. 2014;112:221–226.
21. Rossi L, Sharfo AW, Aluwini S, Dirkx M, Breedveld S, Heijmen B.
First fully automated planning solution for robotic radiosurgery –
comparison with automatically planned volumetric arc therapy for
prostate cancer. Acta Oncol. 2018;57:1490–1498.
22. Rossi L, Romero AM, Milder M, de Klerck E, Breedveld S, Heijmen B.
Individualized automated planning for dose bath reduction in robotic
radiosurgery of bening tumors. PLoS One. 2019;14:e0210279.
23. The effect of planning speed on VMAT plan quality. RaySearch Lab-
oratories. https://www.raysearchlabs.com/globalassets/about‐ove
rview/media‐center/wp‐re‐ev‐n‐pdfs/white‐papers/the‐effect‐of‐pla
nning.pdf (accessed 23 June 2020).
SUPPORTING INFORMATION
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Appendix S1. Tradeoffs of all parameters for prostate plans. Color
represents the percentage difference between SO and VOLO™ plans
calculated as (SO‐VOLO™)*100/SO.
Appendix S2. Population mean DVHs for bladder, rectum and ure-
thra for planning with SO and with VOLO™.
Appendix S3. Tradeoffs of all parameters for lung plans. Color
represents the percentage difference between SO and VOLO™ plans
calculated as (SO‐VOLO™)*100/SO.
Appendix S4. Population mean DVHs OARs as defined for lung
planning with SO and with VOLO™.
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